We've updated our Privacy Policy to make it clearer how we use your personal data. We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement

Therapeutic Delivery – Multimedia

Vaccine Research and Development
Infographic

Vaccine Research and Development

The pandemic has ushered in a vaccines “golden era”. Long-term investment in vaccine manufacturing has been prioritized, as has the pursuit of novel vaccine platforms. In this infographic, we explore recent advances in vaccine research and development.
Nanoparticle
App Note / Case Study

Rapid 4D Analysis of Lipid Nanoparticle Components

Lipid nanoparticles (LNPs) have emerged as effective delivery vehicles for mRNA vaccines and nucleic acid-based drugs. Hence, the analysis of their composition, stability, and biological interactions is essential in drug development and delivery.
Covax-19/Spikogen: A Novel Insect-Cell Expressed Recombinant Protein Vaccine Provides Broad Based Protection Against Covid-19 Infection content piece image
Video

Covax-19/Spikogen: A Novel Insect-Cell Expressed Recombinant Protein Vaccine Provides Broad Based Protection Against Covid-19 Infection

Speaking at the Vaccine Research & Development 2022 online symposium, Nikolai Petrovsky, Professor of Medicine at FLinder's University, delivered his talk on the first Australian-developed vaccine in over 40 years.
Development of Better LNP-Based Genetic Medicines content piece image
eBook

Development of Better LNP-Based Genetic Medicines

Lipid nanoparticles (LNPs) are effective non-viral vectors, which are widely used delivery vehicles for genetic medicines. It is therefore important to understand and limit LNP-related impurities to help ensure genetic product integrity and mitigate risks to patient safety and product efficacy.
Distinguishing Oxidative Impurities From Ionizable Lipids Used in LNP Formulations content piece image
App Note / Case Study

Distinguishing Oxidative Impurities From Ionizable Lipids Used in LNP Formulations

Lipid nanoparticles (LNPs), comprised of ionizable lipids, are used to deliver oligonucleotides to work as therapeutics or to stimulate the immune system, as in the initial mRNA-based COVID vaccines.
Analytical Solutions for mRNA Vaccines and Therapeutics content piece image
How To Guide

Analytical Solutions for mRNA Vaccines and Therapeutics

Messenger RNA (mRNA) therapy enables the body to make the proteins needed to prevent, treat or cure diseases but, unlike traditional biologics, mRNAs are large and delicate molecules that need to be protected by lipid nanoparticles (LNPs) on the journey to reach target cells.
Why Vaccine Developers Need a Charged Aerosol Detector (CAD) content piece image
Video

Why Vaccine Developers Need a Charged Aerosol Detector (CAD)

Watch this short presentation to learn how a high resolution HPLC-CAD platform can provide accurate and fast characterization of your LNP formulations.
How To Ensure Lipid Nanoparticle (LNP) Quality With Adam Crowe content piece image
Video

How To Ensure Lipid Nanoparticle (LNP) Quality With Adam Crowe

In this episode of Teach Me in 10 we are joined by Adam Crowe, manager of analytical development at Precision NanoSystems Inc.
Distinguishing Oxidative Impurities From Ionizable Lipids Using Electron Activated Dissociation content piece image
App Note / Case Study

Distinguishing Oxidative Impurities From Ionizable Lipids Using Electron Activated Dissociation

Lipid nanoparticles (LNPs) comprised of ionizable lipids can be used to deliver oligonucleotides to work as therapeutics or to stimulate the immune system. Detailed and sensitive characterization of the ionizable lipid and its related impurities is necessary to ensure quality, however, obtaining the level of detail needed is challenging with current LC-MS-based methodologies.
Targeting RNA Therapeutics to the Lung: Ten Years On. content piece image
Video

Targeting RNA Therapeutics to the Lung: Ten Years On.

Speaking at the Advances in Drug Discovery & Development 2022 online symposium, Sterghios Moschos delivered his talk on targeted RNA therapeutics in the lung.
Advertisement